Beta-interferons in multiple sclerosis: a single center experience in India.
BACKGROUND
Indian-Asian multiple sclerosis behaves somewhat differently from Western disease. It is not known if the response to beta-interferon is also different.


OBJECTIVE
To demonstrate the decrease in relapses with beta-interferon in Indian patients with multiple sclerosis.


METHODS
Patients with relapsing-remitting or secondary progressive multiple sclerosis with at least two relapses were started on beta-interferon.


RESULTS
Sixteen patients were followed up for a period of 1-3 years. Fifteen had relapsing-remitting multiple sclerosis (MS). The mean number of relapses in these patients before interferons were started was 3.4. The mean yearly relapse rate was 1.3. The mean Kurtzke Expanded Disability Status Scale (EDSS) at the start of beta-interferon therapy in relapsing-remitting MS was 1.7. Ten of these patients were on Avonex((R)) (interferon beta1a) and six (including the patient with secondary progressive MS) were on Betaferon((R)) (interferon beta1b). On follow-up, three patients (two on Avonex((R)) and one on Betaferon((R)) ) had relapses. The respective beta-interferon being received by these patients was continued, with no further relapses. The remaining patients had no relapse or clinical or MRI progression after starting the drug. The side effect profile of the drug in these patients was favorable; although nearly all developed fever on the first day of the injection, only 50% of the patients continued to have fever after 3 months. Two patients developed psychiatric symptoms, requiring discontinuation of the drug.


CONCLUSIONS
Our prospective follow-up study shows that beta-interferons are safe and effective in Indian patients with relapsing-remitting or secondary progressive MS.
Gupta
Salil
S
Department of Neurology, Command Hospital Air Force, Bangalore, India. chickusalil@yahoo.com
Varadarajulu
R
R
Ganjoo
R K
RK
Neurology. 1993 Apr;43(4):655-61
8469318
J Assoc Physicians India. 1996 Nov;44(11):765-7
9251448
Neurology. 1996 Apr;46(4):907-11
8780061
J Neurol Sci. 1975 Oct;26(2):259-70
1176993
Neurology. 1996 Feb;46(2):385-7
8614499
Neurology. 1988 May;38(5):727-9
3362370
AJNR Am J Neuroradiol. 2000 Apr;21(4):702-6
10782781
Neurol India. 1999 Mar;47(1):8-11
10339701
Neurol India. 1999 Mar;47(1):12-7
10339702
Ann Neurol. 1995 Jan;37(1):7-15
7529476
Brain. 1997 Nov;120 ( Pt 11):2059-69
9397021
Acta Neurol Scand. 1980 Nov;62(5):312-21
7468154
J Neuroimmunol. 1999 Jan 1;93(1-2):8-14
10378864
Clin Immunol Immunopathol. 1996 Oct;81(1):1-11
8808634
Ann Acad Med Singap. 1985 Jan;14(1):32-6
4004124
Neurology. 1996 Jan;46(1):12-8
8559358
Neurol India. 1999 Mar;47(1):18-21
10339703
Neurology. 1999 Nov 10;53(8):1622-7
10563602
Neurology. 1983 Nov;33(11):1444-52
6685237
Ann Neurol. 2001 Jul;50(1):121-7
11456302